Physician profile
Simran Sidhu
NPI 1821445040
$2,994.51
in general payments reported to CMS, 2019-2025
19 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2023: $188 · 2024: $1,401 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,552 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,551.94 |
| Education | $142.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.79 | 2023-2025 | |
| Janssen Biotech, INC. | $476.21 | 2024-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $379.16 | 2021-2024 | |
| Merz North America, INC. | $218.86 | 2021 | |
| Gilead Sciences, INC. | $193.40 | 2024-2025 | Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $142.43 | 2024-2025 | Xifaxan |
| Celltrion USA INC. | $92.46 | 2023-2025 | Zymfentra, Vegzelma |
| Takeda Pharmaceuticals U.S.A., INC. | $91.16 | 2023-2025 | Entyvio |
| Pfizer INC. | $85.80 | 2024-2025 | |
| Madrigal Pharmaceuticals | $82.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $73.36 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $64.91 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $63.23 | 2025 | Suflave, Sutab |
| Lilly USA, LLC | $54.81 | 2024 | Omvoh |
| Ardelyx, INC. | $47.96 | 2023-2025 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $36.34 | 2024 | Zeposia |
| Azurity Pharmaceuticals, INC. | $29.65 | 2025 | Sutab |
| Nestle Healthcare Nutrition INC. | $26.69 | 2023 | |
| Novo Nordisk INC | $14.03 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simran Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.